Abstract:e13538 Background: Currently, with the advances in detection techniques, such as next generation sequencing (NGS), more and more rare or atypical EGFR mutations had been identified. Such as exons 18-25 kinase domain duplications (KDD) and EGFR fusions (EGFR-RAD51 or EGFR-PURB), the importance of EGFR signaling in the pathogenesis of lung cancer and the efficacy of EGFR-TKI treatment had been demonstrated. The aim of this study was to evaluate the prevalence of EGFR fusions in Chinese NSCLC patients, and to study the association between these molecular alterations and clinicopathological characteristics in these patients. Methods: A multicenter study in China was initiated from February 2014, and NSCLC patients have been enrolled as of December 2017. A total of 2410 patients with NSCLC (non-squamous/squamous =2061/349) were screened by using next-generation sequencing (NGS)-based 381 genes panel assay for detecting EGFR fusions. Results: Of this entire cohort, just two (0.08%) patients were identified with an EGFR-SEPT14 fusion and an EGFR-RAD51 fusion. These two patients was that a 62-year-old never smoking female, who was diagnosed with lung adenocarcinoma and a 48-year-old male with a 32 pack-year smoking history, who was diagnosed with lung adenocarcinoma. The first patient: EGFR-SEPT14 fusion driven NSCLC responding to icotinib, there were no treatment-related adverse events, including abnormal hepatic, renal function, gastrointestinal reactions, rashes, and cordis damage. Thus far, after several months, the disease is stable and she is continuing treatment with icotinib; The second patient: EGFR-RAD51 fusion driven NSCLC responding to erlotinib will be presented. The patient was considered to have a partial response (PR) to erlotinib. During treatment with erlotinib, no abnormal hepatic and renal function occurred. Conclusions: The frequency of EGFR fusions in Chinese patients with NSCLC is extremely rare (0.08%). The NGS assay provides a novel diagnostic tool. In the future, we can explore differences in the acquired mechanism underlying EGFR TKIs between sensitive EGFR mutations and other uncommon variant NSCLC patients.

A Novel Acquired EGFR-SEPT14 Fusion Confers Differential Drug Resistance to EGFR Inhibitors in Lung Adenocarcinoma.

Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement

The KIF5B-RET Fusion Gene Mutation As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

EP1.14-46 the KIF5B-RET Fusion As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

Prevalence of EGFR Gene Fusions in a Large Cohort of Chinese Patients with Non-Small Cell Lung Cancer (NSCLC).

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review

EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

P3.01-104 EGFR-RAD51 Fusion Variant in Lung Adenocarcinoma and Response to Erlotinib: A Case Report

EGFR Tyrosine Kinase Inhibitor (TKI) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Uncommon EGFR Mutations: A Real-World Study in China.

Mutations of the epidermal growth factor receptor gene in NSCLC patients.

Characterization of Acquired Receptor Tyrosine Kinase Fusions As Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors

EGFR with TKI-sensitive Mutations in Exon 19 is Highly Expressed and Frequently Detected in Chinese Patients with Lung Squamous Carcinoma.

P3.CR-09 MET-UBE2H fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma" with "MET fusion as a novel mechanism of acquired EGFR resistance in lung adenocarcinoma

The novel EGFR mutations (p.E746_S752delinsI, p.T751_I759delinsG, p.L747_S752delinsAA) in patients with non-small cell lung cancer and the clinical treatment strategy: three case reports

Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.

The Clinicopathological and Molecular Characteristics of Resected EGFR‐mutant Lung Adenocarcinoma

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors

RET Fusion in First/third-Generation EGFR-TKIs Resistance in Advanced Non-Small Cell Lung Cancer.

Uncommon de novo EGFRT790M-Mutant NSCLC characterized with unique genetic Features: Clinical response and acquired resistance to the third-generation EGFR-TKIs treatment